SCHEMBL209575

SCHEMBL209575

O=C(c1ccc(-c2cc(Cl)c(C[C@@H]3CCN([C@H]4CC[C@@H](O)CC4)C3=O)c(Cl)c2)cc1)N1CCN(CC(F)(F)F)CC1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 2/20 0.35
BCR P11274 2/20 0.35
HRH3 Q9Y5N1 4/20 0.34
LSS P48449 1/20 0.34
AXL P30530 1/20 0.33
FLT3 P36888 1/20 0.33
TYRO3 Q06418 1/20 0.33
MERTK Q12866 1/20 0.33
MET P08581 1/20 0.33
LRRK2 Q5S007 2/20 0.33
NPY1R P25929 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
STAT3 P40763 1/20 0.33
BMPR1B O00238 1/20 0.33
BMPR1A P36894 1/20 0.33
ACVRL1 P37023 1/20 0.33
ACVR1 Q04771 1/20 0.33
HTR2B P41595 1/20 0.33
SIGMAR1 Q99720 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL207707 1.00 ABL1 (0.35) ABL1BCRHRH3LSSAXL
SCHEMBL207709 1.00 ABL1 (0.35) ABL1BCRHRH3LSSAXL
SCHEMBL207708 1.00 ABL1 (0.35) ABL1BCRHRH3LSSAXL
SCHEMBL209061 0.92 HSD11B1 (0.39) ABL1BCRHRH3LSS
SCHEMBL381727 0.91 NPY1R (0.37) ABL1BCRLSSMETNPY1R
SCHEMBL209599 0.91 HRH3 (0.37) ABL1BCRHRH3MET
SCHEMBL381728 0.91 NPY1R (0.37) ABL1BCRLSSMETNPY1R
SCHEMBL209598 0.91 HRH3 (0.37) ABL1BCRHRH3MET
SCHEMBL3124490 0.90 FASN (0.35) ABL1BCRLSSMETLRRK2
SCHEMBL3124484 0.90 FASN (0.35) ABL1BCRLSSMETLRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2016047-B1 BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11- BETA-HYDROXYSTEROID DEHYDROGENASE 1 LILLY CO ELI (US) 2013-08-28 EP claimed
US-8088776-B2 Biphenyl amide lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 ELI LILLY AND COMPANY (US) 2012-01-03 US claimed
US-20090156571-A1 BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 ELI LILLY AND COMPANY 2009-06-18 US claimed
EP-2016047-B1 BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11- BETA-HYDROXYSTEROID DEHYDROGENASE 1 LILLY CO ELI (US) 2013-08-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156571-A1 BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 HSD11B1, HSD17B1, HSD11B2 ABL1 3838/4885BCR 332/4885HRH3 1964/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.